Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 15, 2024

SELL
$28.03 - $51.82 $12.1 Million - $22.3 Million
-430,972 Reduced 26.94%
1,169,028 $52.6 Million
Q4 2019

Feb 11, 2020

BUY
$14.08 - $18.5 $22.5 Million - $29.6 Million
1,600,000 New
1,600,000 $22.5 Million

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $2.3B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Medicxi Ventures Management (Jersey) LTD Portfolio

Follow Medicxi Ventures Management (Jersey) LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Medicxi Ventures Management (Jersey) LTD, based on Form 13F filings with the SEC.

News

Stay updated on Medicxi Ventures Management (Jersey) LTD with notifications on news.